Third generation PCSK9-inhibitors

Article Health Care Sciences & Services

Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study

Kausik K. Ray et al.

Summary: The SANTORINI study found that in Europe between 2020 and 2021, statin monotherapy was the main approach to lipid management for high-risk and very high-risk cardiovascular patients, with only one-fifth achieving the recommended LDL-C goals. The study results raised questions about whether there have been changes in the treatment landscape or if gaps still exist.

LANCET REGIONAL HEALTH-EUROPE (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C

Julius L. Katzmann et al.

Summary: Many patients with high cardiovascular disease risk do not achieve the recommended LDL-C targets. Prescription trends for non-statin lipid-lowering therapies have increased in Germany, but are infrequent among general practitioners. Combination therapy with fixed-dose combinations leads to greater reduction in LDL-C, but a significant proportion of patients still have uncontrolled LDL-C levels.

CLINICAL RESEARCH IN CARDIOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Gene Therapy Targeting PCSK9

Julius L. Katzmann et al.

Summary: Recent developments in cardiovascular prevention research have shown successful treatments for LDL hypercholesterolemia, such as inhibiting the PCSK9 gene or using specific drugs. These methods have led to long-term reductions in LDL cholesterol levels and have the potential to fundamentally change our approach to cardiovascular prevention.

METABOLITES (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease

Michelle L. O'Donoghue et al.

Summary: Long-term use of evolocumab to lower LDL-C levels is associated with low rates of adverse events, which do not exceed those in the placebo group. Over time, the use of evolocumab also leads to further reduction in cardiovascular events.

CIRCULATION (2022)

添加到收藏夹

Article Medicine, General & Internal

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Antonio J. Vallejo-Vaz et al.

Summary: This study characterized the adult population with heterozygous familial hypercholesterolaemia using data from the FHSC global registry, highlighting the challenges in prevention and management of the condition. Early detection and greater use of combination therapies are needed to reduce the global burden of familial hypercholesterolaemia.

LANCET (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems